Journal Article

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Hose, Dirk, Mai, Elias K., Seckinger, Anja, Salwender, Hans J., Munder, Markus, Weinhold, Niels, Huhn, Stefanie, Goldschmidt, Hartmut, Miah, Kaya, Benner, Axel, Berlanga, Oscar, Blau, Igor W., Weisel, Katja C., Poos, Alexandra M., Hänel, Mathias, Bertsch, Uta, Scheid, Christof, Jauch, Anna, Raab, Marc S.

2023

Overview

Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and performed a retrospective MS analysis at baseline (480 patients) and at the pre-defined, consecutive time points after induction (444 patients), prior to maintenance (305 patients) and after one year of maintenance (227 patients). We found that MS negativity was significantly associated with improved progression-free survival (PFS) even in patients with complete response (CR) at all investigated follow-up time points. The prognostic impact was independent of established risk factors, such as the revised International Staging System. Combining MS and baseline cytogenetics improved the prediction of outcome: MS-positive patients with high-risk cytogenetics had a dismal PFS of 1.9 years (95% confidence interval [CI]: 1.6–2.3 years) from the start of maintenance. Testing the value of sequential MS prior to and after one year of maintenance, patients converting from MS positivity to negativity had an excellent PFS (median not reached) while patients converting from MS negativity to positivity progressed early (median 0.6 years, 95% CI: 0.3-not reached). Among patients with sustained MS positivity, the baseline high-risk cytogenetic status had a significant impact and defined a group with poor PFS. Combining minimal residual disease (MRD) in the bone marrow and MS allowed the identification of double negative patients with a favorable PFS (median 3.33 years, 95% CI: 3.08-not reached) and no overall survival events. Our study provides strong evidence that MS is superior to conventional response monitoring, highlighting the potential of MS to become a new standard. Our data indicate that MS should be performed sequentially and combined with baseline disease features and MRD to improve its clinical value. Clinical Trials Register: EudraCT No. 2010-019173-16

• Publisher: Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group
• Subject: 14/32 / 45/77 / 631/67/1990/804 / 692/308/575 / 692/499 / 692/699/1541/1990/804 / 692/700/139/1512 / 82/58 / Biomedical and Life Sciences / Biomedicine / Bone Marrow / Cancer Research / Cytogenetics / Hematology / Humans / Mass Spectrometry / Multiple myeloma / Multiple Myeloma - diagnosis / Multiple Myeloma - drug therapy / Neoplasm, Residual - diagnosis / Oncology / Prognosis / Retrospective Studies / Scientific imaging / Treatment Outcome